In a landmark decision concerning SPC for Durvalumab, the District Court of The Hague upheld the Dutch Intellectual Property Office’s (IPO) refusal to grant a Supplementary Protection Certificate (SPC) for AstraZeneca’s cancer immunotherapy drug Durvalumab, marketed as Imfinzi®. Durvalumab is an anti-PD-L1 antibody used in treating various cancers, and the refusal of SPC status has … Read more
On Nov 5, 2025, the Patents Court handed down an important interim injunction decision in Dr Reddy’s Laboratories (UK) Ltd v Boehringer Ingelheim International GmbH, neutral citation EWHC 2834 (Pat). Michael Tappin KC, sitting as a Deputy Judge, granted interim relief restraining Dr Reddy’s from dealing in empagliflozin (the active in Jardiance) in the UK … Read more
UK Court of Appeal Judgment on Dapagliflozin Patent UK Court of Appeal Judgment: Dapagliflozin Patent In a recent landmark judgment, the UK Court of Appeal upheld the High Court’s April 2025 decision invalidating the UK equivalent patent of EP1506211B1 (expired on May 14, 2023) for Dapagliflozin and its associated Supplementary Protection Certificate (SPC) (Expiry Date: … Read more
